Patient advocate, Michele Nadeem Baker, hosts Boyu Hu, MD, Director of Lymphoma and Chronic Lymphocytic Leukemia at the Huntsman Cancer Institute at the University of Utah for a discussion on fixed duration treatment.

Physician assistant Jill Miller shares what CLL patients really need to know about fixed-duration treatment. Learn how to manage side effects, what to expect month by month, when treatment ends, and how to navigate the emotional transition from active therapy to surveillance.

In this episode of Patient Power’s podcast Unraveling Cancer, patient host Michele Nadeem-Baker sits down with Lucy Potter, MD, MPH, MD Anderson, for a conversation about one of the most common challenges in cancer care: fatigue. They explore practical behavioral strategies to ease day-to-day exhaustion, discuss when medications may be helpful, and highlight key tests that can uncover underlying causes.

In this episode of the Patient Power podcast, Unraveling Cancer, patient host, Michele Nadeem-Baker is joined by Deborah Stephens, DO, UNC at Chapel Hill, for a conversation about choosing a treatment for CLL, when to consider a clinical trial and the pros and cons of fixed duration vs continuous therapy.

In this episode of the Patient Power podcast, Unraveling Cancer, patient host, Michele Nadeem-Baker is joined by Kerry Rogers, MD, from The Ohio State University, for a conversation about preparing for an upcoming doctor’s visit, how to have a productive conversation about treatment decisions and what to do when you don’t feel you are being heard.

In this episode of the Patient Power podcast, Unraveling Cancer, patient host, Brad Adams is joined by Thomas Kipps, MD UC San Diego, for a conversation about why the move from chemotherapy to targeted treatments is a game changer for older CLL patients and those with co-morbidities.

In this episode of the Patient Power podcast, Unraveling Cancer, patient host Larry Fagan is joined by Benjamin Heyman, MD, UC San Diego, for a conversation about frontline therapies for mantle cell lymphoma, the results from the ECHO trial, and the role of combination treatments in a frontline setting moving forward.